Our latest technical analysis of Pharming Grp NV (OTC:PHGUF)
 | By Gabriel Shpitalnik | Macroaxis Story |
As many of us are excited about healthcare space, it is fair to digest Pharming Grp NV within current market trends. As we have suggested previously, Pharming Grp is beginning its dip as shareholders shift to be more bearish due to the increased sector volatility. The returns on investing in Pharming Grp and the market returns of the last few months appear uncorrelated. Unsteady basic indicators of the firm may also indicate signs of longer-term losses for Pharming shareholders. Pharming Grp NV is scheduled to announce its earnings today.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
Pharming Grp's average rating is Strong Buy from 2 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Pharming Grp market sentiment investors' perception of the future value of Pharming. Let us look at a few aspects of Pharming technical analysis.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Pharming Group. Your research has to be compared to or analyzed against Pharming Group's peers to derive any actionable benefits. When done correctly, Pharming Group's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Pharming Group NV.
Using predictive technical analysis, we can analyze different prices and returns patterns and diagnose historical swings to determine the real value of Pharming Group NV. In general, sophisticated investors focus on analyzing Pharming Group stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Pharming Group's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Pharming Group's intrinsic value. In addition to deriving basic predictive indicators for Pharming Group, many experienced traders also check how macroeconomic factors affect Pharming Group price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Pharming Group's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Watch out for price decline
Please consider monitoring Pharming Group on a daily basis if you are holding a position in it. Pharming Group is trading at a penny-stock level, and the possibility of delisting is much higher compared to other pink sheets. However, just because the pink sheet is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Pharming Group stock to be traded above the $1 level to remain listed. If Pharming Group pink sheet price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How does Pharming Stands against Peers?
Analyzing Pharming Group competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Pharming Group across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out Pharming Group Competition DetailsDetailed Outlook On Pharming Group
This firm has a beta of -0.0718. Let's try to break down what Pharming's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pharming Grp will likely underperform. The beta indicator helps investors understand whether Pharming Grp moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Pharming deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The company reported the revenue of 218.53 M. Net Income was 38.43 M with profit before overhead, payroll, taxes, and interest of 165.09 M.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Pharming Group NV. Please refer to our Terms of Use for any information regarding our disclosure principles.